ARCH Venture Partners
ARCH Venture Partners, one of the largest early stage technology venture firms in the U.S., invests in the development of seed and early stage advanced technology companies that have the potential to grow rapidly into successful businesses. ARCH enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions, corporate research groups and national laboratories.
ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH’s limited partners include major corporations, pension funds, university endowments, financial institutions, and private investors.
The partnership is led by eight managing directors, including four co-founders who have worked together for more than 25 years. They are supported by a team of partners, venture partners, associates, and technology specialists.
Founded in 2020, Bering Capital is a venture capital firm based in San Francisco, California. The firm is primarily focused on biotech and medtech innovations.
We invest in extraordinary people and cutting edge biotech and medical technology companies. We are experts in identifying critical problems, and knowing when to act. We learned invaluable lessons from several of the early pioneers of Silicon Valley and venture capital, and have built on them. From our own entrepreneurial ventures and experience, we understand how to shape the early DNA of a company to set it up for success.
Canaan Partners is a global venture capital firm that invests in people with visionary ideas. The kind that not only result in new and valuable technology, but game-changing healthcare startups as well.
We were early investors in some of the world's leading technology companies, including PrimeSense, SuccessFactors and Lending Club and healthcare stars like Cerexa, Chimerix and Advanced BioHealing.
All of which makes one thing perfectly clear. When people are your priority, good things happen.
GreatPoint Ventures is a thesis driven venture capital firm that invests in solutions to important global problems. GreatPoint looks for driven entrepreneurs and start-up businesses addressing clear pain-points in industry with innovative technology. Comprised of entrepreneurs and operators, GreatPoint actively collaborates with founders and their teams to build great businesses. GreatPoint has invested in the world's fastest database, the leader in predictive analytics for the industrial world, a marketplace to reinvent the US healthcare system, and pioneers in cancer diagnostics and therapeutics, among other break-through innovations.
Helsinn Investment Fund
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Drawing on Helsinn’s 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
InterVest Co., Ltd. is one of the largest independent venture capital firms in Korea specializing in startups and early stage business investments. With over $1.2 billion under management, InterVest finances growth stage equity investments to pre-initial public offerings through mezzanine and bridge transactions.
Since its founding in 1999, InterVest has been an innovator and the most active investor in the Korean VC industry. It was Korea’s first VC fund with Foreign LPs and established Korea’s first government-supported global Bio Fund and SE Asia Focused Fund. The company was selected as a "10-Year Consecutive A-rated Venture Capital Investor" by the Ministry of SMEs and Startups in Korea.
Magnetar Capital is a leading alternative asset manager with offices in Evanston, Ill., Houston and London. Founded in 2005, Magnetar was built on the belief that new opportunities existed for a firm specifically structured to remove common barriers among various investment styles – like quantitative and qualitative, short and long duration, and beyond.
At Magnetar, we are innovators, dissatisfied with the status quo. We seek to generate tomorrow’s diversifying return streams by challenging today’s investment norms. We work to identify differentiated opportunities where we believe we can create a strategic advantage by engineering and scaling our processes and attempting to structure our investments to be profitable across a wide array of outcomes.
As part of our mission to deliver diversifying returns to investors, we invest growth capital in businesses that drive the real economy. We invest across geographies, in both public and private transactions.
MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 44 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No. 1 for cancer care in the U.S. News & World Report’s “Best Hospital’s” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
RiverVest Venture Partners
RiverVest Venture Partners® is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. Because of its extensive operating expertise, RiverVest is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
Yonjin Venture LLC is the North America and Europe investment arm of Yongjin Group (Yongjin) and the sister firm of Yonghua Capital (Yonghua) both based in China with headquarters in Shanghai. Established in 2018, the firm is based in in Cambridge, Massachusetts..
Yonjin Venture LLC specializes in early- and mid-stage life science companies. We are interested in innovative technologies in therapeutics, diagnostics and medical devices.